A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due diligence, data protection, and trial locations, including sensitive sites like Xinjiang and military hospitals. Lawmakers have requested detailed documentation by July 17. The probe highlights rising US-China tensions over scientific research and national security risks related to biomedical data. The companies have responded cautiously, with Merck emphasizing ethical standards and others withholding comments.
The global Oxidative Stress Assay Market, valued at $1.31 billion in 2025, is projected to reach $3.25 billion by 2035, growing at a CAGR of 9.53%. Growth is fueled by rising chronic diseases, pharmaceutical innovation, and advances in biomarker diag...
Moderna's stock surged 14% to a 52-week high following an FDA advisory panel's unanimous endorsement of its flu vaccine for adults 50 and older, a key step before the August 2026 approval date. The rally also reflects optimism from Moderna's recent S...
